P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir

Molecular Pharmacology

Volumn 59, Issue 4, 2001, Pages 806-813

  Huisman, Maarten T ^a   Smit, Johan W ^a   Wiltshire, Hugh R ^b   Hoetelmans, Richard M W ^c   Beijnen, Jos H ^c   Schinkel, Alfred H ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b ROCHE PRODUCTS LTD   (United Kingdom)

^c SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN P; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG PENETRATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0035063261     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.59.4.806     Document Type: Article

References (40)

1. Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers
2. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833
3. Ritonavir and saquinavir combination therapy for the treatment of HIV infection
4. Placental transfer of ritonavir with zidovudine in the ex vivo placental perfusion model
5. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes
6. Re-emergence of HIV after stopping therapy
7. The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues
8. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir
9. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
10. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: Potential contribution to high first-pass metabolism
11. Biochemistry of multidrug resistance mediated by the multidrug transporter
12. Interactions of HIV protease inhibitors with ATP-dependent drug export proteins
13. ABC transporters: From microorganisms to man
14. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir
15. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors
16. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative
17. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
18. Treatment response and durability of a double protease inhibitor therapy with saquinavir and ritonavir in an observational cohort of HIV-1-infected individuals
19. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir
20. Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein
21. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors
22. Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: Mechanism-based inactivation of cytochrome P4503A by ritonavir
23. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction
24. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes
25. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter
26. Stage-specific distribution of P-glycoprotein in first-trimester and full-term human placenta
27. Antiretroviral therapy for pregnant women
28. Mechanisms and timing of mother-to-child transmission of HIV-1
29. Transplacental effects of 3′-azido-2′,3′-dideoxythymidine (AZT): Tumorigenicity in mice and genotoxicity in mice and monkeys
30. Saquinavir soft-gel capsule formulation. A review of its use in patients with HIV infection
31. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor
32. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors
33. Human immunodeficiency virus protease inhibitors
34. HIV-1 and HAART: A time to cure, a time to kill
35. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A
36. Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure
37. Heterologous expression of various P-glycoproteins in polarized epithelial cells induces directional transport of small (type 1) and bulky (type 2) cationic drugs
38. Predicting the optimal dose of saquinavir via modelling of dose-exposure and exposure-effect relationships
39. Cellular localization of the multidrug-resistance gene product P- glycoprotein in normal human tissues
40. Simultaneous quantitative determination of the HIV protease inhibitors amprenavir, indinavir, nelfinavir, ritonavir and saquinavir in human plasma by ion-pair high-performance liquid chromatography with ultraviolet detection